More than 1000 patients have been recruited by Panthera Biopartners the UK’s largest SMO (Site Management Organisation) who recruit patients and runs clinical trials for the pharmaceutical industry. More than a 100,000 patients came forward to take part in the trials but this boiled down to just over a 1000 who met the conditions of each study.
Panthera, which has six sites across the UK, has in the last two years been the top recruiter globally in four studies, the top recruiter in the UK on six other studies and has achieved first patient in globally or in the UK on nine studies. It also became the first UK public or commercial clinical trial organisation to become part of the Parexel Site Alliance Vaccine Network.
Chris Dodd, Chief Commercial Officer at Panthera, commented “The UK is particularly well placed to become a centre for running commercial trials with top-quality PIs, a diverse population and experienced clinical trial sites.”
Panthera Biopartners has again broadened the range of therapy areas it can run clinical trials in to include not only vaccines, cardiovascular, general medicine, diabetes, neurology, respiratory, dermatology and rheumatology but also specialist areas such as oncology, NASH and early dementia trials.
The UK remains a top destination for clinical trials due to its dense and diverse population, high-calibre healthcare professionals, and recent regulatory advancements by the Medicines and Healthcare Products Regulatory Agency (MHRA). Changes to streamline regulatory reviews have enhanced the UK’s competitiveness against European countries while offering cost advantages over the US.